Ezetimibe side effects and hair loss is a concern raised by some patients taking this commonly prescribed cholesterol-lowering medicine. Ezetimibe (brand name Ezetrol) works by reducing cholesterol absorption in the small intestine and is used alone or alongside a statin to lower LDL cholesterol. While its established side effects are generally mild, alopecia does appear in post-marketing reports and is listed in the UK Summary of Product Characteristics (SmPC) at a frequency of 'not known'. This article examines what the evidence says, explores other likely causes of hair loss, and explains when to seek medical advice.

Common and Reported Side Effects of Ezetimibe

The most commonly reported side effects of ezetimibe are gastrointestinal disturbances, fatigue, and headache; rare but serious effects include myopathy, hepatitis, pancreatitis, and hypersensitivity reactions.

Experiencing these side effects? Our pharmacists can help you navigate them →

Ezetimibe is a lipid-lowering medicine used to reduce LDL cholesterol, either alone or in combination with a statin. It works by selectively inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, thereby reducing the absorption of dietary and biliary cholesterol. Unlike statins, it does not act on the liver's cholesterol synthesis pathway, which gives it a distinct side effect profile.

According to the Summary of Product Characteristics (SmPC) for ezetimibe (Ezetrol), the NHS medicines information page, and the BNF, the most commonly reported side effects include:

• Gastrointestinal disturbances – such as abdominal pain, diarrhoea, and flatulence (common: affects up to 1 in 10 people)

• Fatigue – a general sense of tiredness or low energy (common)

• Headache – reported in a small proportion of users (common)

• Elevated liver enzymes – particularly when used alongside a statin (uncommon)

• Myalgia (muscle aches) – more frequently reported in combination therapy (uncommon)

Less common but clinically important adverse effects include myopathy and, rarely, rhabdomyolysis — particularly when ezetimibe is used with a statin. Cholelithiasis (gallstones) has been reported when ezetimibe is used with a fibrate. Thrombocytopenia is listed as a rare adverse reaction in the SmPC.

Serious but rare adverse effects include hypersensitivity reactions (such as rash or angioedema), hepatitis, and pancreatitis. These are uncommon but warrant prompt medical attention if they occur.

Urgent red flags — seek immediate medical help if you develop:

• Yellowing of the skin or eyes (jaundice), dark urine, or pale stools — possible signs of liver injury

• Severe upper abdominal pain radiating to the back — possible pancreatitis

• Unexplained muscle pain, weakness, or tenderness, especially with dark urine — possible myopathy or rhabdomyolysis

• Swelling of the face, lips, tongue, or throat, or difficulty breathing — possible severe allergic reaction (call 999 or go to A&E immediately)

Overall, ezetimibe is considered well tolerated by most patients. Understanding its established side effect profile is important when evaluating whether a symptom such as hair loss could plausibly be attributed to this medication.

Not sure if this is normal? Chat with one of our pharmacists →

Is Hair Loss Linked to Ezetimibe?

Alopecia is listed in the ezetimibe SmPC under post-marketing adverse reactions at 'frequency not known', meaning it cannot be excluded but is not an established common side effect, and no direct causal link has been confirmed.

Hair loss (alopecia) has been reported in post-marketing surveillance for ezetimibe and is listed in the UK SmPC under adverse reactions with a frequency of 'not known' (meaning it cannot be estimated from available data). It is not considered a common side effect, and a direct causal link has not been established. Patients and clinicians should be aware of this distinction: the fact that alopecia appears in post-marketing reports means it cannot be entirely dismissed, but it does not confirm that ezetimibe routinely causes hair loss.

When patients take ezetimibe alongside a statin — a common prescribing pattern — attributing hair loss to one specific agent is particularly difficult. Some statins, including simvastatin and atorvastatin, also have rare post-marketing reports of alopecia, which may complicate the picture further.

If you notice hair thinning or shedding after starting ezetimibe, it is important not to stop taking your medication without first speaking to your GP or pharmacist. The cardiovascular benefits of cholesterol-lowering therapy are well established, and any decision to stop or switch treatment should be made with clinical guidance. Your doctor may consider a supervised dechallenge (stopping the medicine under observation) to assess whether hair regrowth occurs, but this must be weighed carefully against your individual cardiovascular risk.

What the Evidence and MHRA Data Say

The IMPROVE-IT trial did not identify alopecia as a significant adverse event, and no formal MHRA or EMA safety signal specifically addressing ezetimibe and hair loss has been issued as of mid-2025.

The MHRA's Yellow Card scheme is the UK's pharmacovigilance system, allowing patients and healthcare professionals to report suspected adverse drug reactions. A review of Yellow Card data and published literature indicates that reports of hair loss associated with ezetimibe are rare. Spontaneous reports of this kind are hypothesis-generating rather than confirmatory: they cannot be used to estimate the frequency of an adverse reaction or to prove causality, as they do not account for confounding factors such as concurrent medications, underlying medical conditions, or nutritional status.

The landmark IMPROVE-IT trial (Cannon et al., NEJM 2015) — which compared ezetimibe plus simvastatin against simvastatin alone in over 18,000 patients — did not identify alopecia as a statistically significant adverse event in the ezetimibe arm. This large-scale evidence base provides reasonable reassurance that hair loss is not a common pharmacological consequence of ezetimibe use, though the trial was not designed to detect rare adverse reactions.

Spontaneous post-marketing reports of alopecia have also been submitted to international regulatory databases. The EMA's European Public Assessment Report (EPAR) for ezetimibe and the UK SmPC reflect these post-marketing signals by listing alopecia under adverse reactions at 'frequency not known'. No formal safety signal update specifically addressing ezetimibe and hair loss has been issued by the MHRA or EMA to date (as of mid-2025).

The current weight of evidence does not support ezetimibe as a direct or common cause of hair loss, but the post-marketing reports mean the possibility of an individual reaction cannot be entirely excluded. Patients and healthcare professionals are encouraged to report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk, as ongoing surveillance is essential for detecting rare or delayed drug effects. Patients can submit Yellow Card reports directly, which helps build a more complete picture of real-world drug safety.

Other Causes of Hair Loss to Consider

Hair loss in patients taking ezetimibe is more commonly explained by telogen effluvium, androgenetic alopecia, thyroid dysfunction, iron deficiency, or other medications than by the drug itself.

When a patient taking ezetimibe reports hair loss, it is clinically important to consider the wide range of alternative causes before attributing the symptom to the medication. Hair loss is extremely common in the general population and has numerous well-recognised causes unrelated to lipid-lowering therapy. NICE Clinical Knowledge Summaries (CKS) and NHS guidance provide a useful framework for primary care evaluation.

Common causes of hair loss to consider include:

• Telogen effluvium – a temporary, diffuse shedding often triggered by physical or emotional stress, illness, surgery, or significant weight loss, typically occurring 2–3 months after the trigger event; usually self-limiting

• Androgenetic alopecia – the most common form of hair loss in both men and women, driven by genetic and hormonal factors

• Thyroid dysfunction – both hypothyroidism and hyperthyroidism can cause diffuse hair thinning; thyroid disease is also more prevalent in patients with dyslipidaemia

• Iron deficiency – a frequently overlooked cause, particularly in premenopausal women; assessed via serum ferritin

• Nutritional deficiencies – including zinc or vitamin D deficiency, where clinically indicated; note that routine biotin supplementation is not generally recommended and biotin can interfere with thyroid function and troponin laboratory assays

• Autoimmune conditions – such as alopecia areata or lupus

• Other medications – including anticoagulants (e.g., warfarin, heparin), antidepressants, antihypertensives (e.g., beta-blockers), antithyroid drugs, valproate, retinoids, and hormonal therapies

• Androgen excess in women – features such as irregular menstrual cycles or hirsutism alongside hair loss may warrant endocrine evaluation

Given that many patients prescribed ezetimibe are middle-aged or older — a demographic in which androgenetic alopecia and thyroid disease are more prevalent — coincidental timing is a plausible explanation in many cases.

A thorough medical history and targeted blood tests guided by clinical findings (which may include thyroid function tests, full blood count, serum ferritin, and vitamin D where deficiency is suspected) are a sensible first step in evaluating unexplained hair loss.

Seek prompt dermatology referral if you notice: scalp inflammation, scarring, pustules, persistent pain or itch, or rapidly progressive patchy loss — these may suggest a scarring alopecia or other condition requiring specialist assessment. The British Association of Dermatologists (BAD) provides patient information on conditions such as alopecia areata and telogen effluvium.

When to Speak to Your GP or Pharmacist

Speak to your GP if hair loss is significant, progressive, or accompanied by other symptoms, but do not stop ezetimibe without medical advice as this may increase cardiovascular risk.

If you have started ezetimibe and noticed changes to your hair, it is reasonable to raise this with your GP or pharmacist, particularly if the hair loss is significant, progressive, or causing distress. However, it is important not to stop taking ezetimibe without medical advice, as doing so could increase your cardiovascular risk — especially if it has been prescribed following a cardiac event or as part of a secondary prevention strategy.

Contact your GP promptly if you experience:

• Sudden or patchy hair loss, which may suggest alopecia areata or another underlying condition

• Hair loss accompanied by fatigue, weight changes, feeling cold, or constipation — which could indicate thyroid dysfunction

• Muscle pain, weakness, or dark urine whilst taking ezetimibe (particularly in combination with a statin), as these may indicate myopathy or rhabdomyolysis

• Yellowing of the skin or eyes, dark urine, or pale stools — possible signs of liver injury

• Severe upper abdominal pain — possible pancreatitis

• Any side effect that is persistent, worsening, or significantly affecting your quality of life

Seek emergency care immediately (call 999 or go to A&E) if you develop signs of a severe allergic reaction, including swelling of the face, lips, tongue, or throat, or difficulty breathing. If you cannot reach your GP and need urgent advice, contact NHS 111.

Your pharmacist can also provide valuable guidance on whether any other medicines you are taking — including over-the-counter products or supplements — could be contributing to hair loss. A medicines review may help identify potential interactions or overlapping side effects.

Managing Side Effects and Treatment Alternatives

If ezetimibe is suspected to contribute to hair loss, a supervised dechallenge may be considered, with alternative lipid-lowering options including PCSK9 inhibitors, bempedoic acid, or inclisiran available under NICE-approved pathways.

If a thorough clinical assessment suggests that ezetimibe may be contributing to hair loss — even in the absence of a confirmed causal link — your GP may consider a supervised trial of stopping or switching the medication to assess whether hair regrowth occurs. This decision must always be balanced against the cardiovascular benefits of cholesterol-lowering treatment and should not be undertaken without professional guidance.

For patients who cannot tolerate ezetimibe or who experience troublesome side effects, several alternative or adjunctive lipid-lowering strategies are available within NICE-aligned prescribing frameworks (see NICE NG238: Cardiovascular disease — risk assessment and lipid modification):

• Statin optimisation – adjusting the dose or switching to a different statin (for example, from simvastatin to rosuvastatin) may improve tolerability

• PCSK9 inhibitors – evolocumab (NICE TA394) and alirocumab (NICE TA393) are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia, including familial hypercholesterolaemia or established cardiovascular disease, who cannot achieve adequate LDL reduction with standard therapy; initiation is via specialist or shared-care pathways according to local eligibility criteria

• Bempedoic acid – an oral agent that inhibits cholesterol synthesis upstream of statins; NICE TA694 recommends bempedoic acid (with or without ezetimibe) for adults with primary hypercholesterolaemia or mixed dyslipidaemia who are statin-intolerant or in whom a statin is contraindicated, and who require further LDL lowering

• Inclisiran – a small interfering RNA therapy administered by subcutaneous injection twice yearly; NICE TA733 recommends inclisiran for adults with primary hypercholesterolaemia or mixed dyslipidaemia and established cardiovascular disease, initiated within specialist or NHS-commissioned pathways

For hair loss itself, management depends on the underlying cause. If nutritional deficiencies are identified, targeted supplementation may be appropriate. Evidence-based options for androgenetic alopecia include topical minoxidil, available over the counter. Dermatology referral is appropriate for persistent, severe, or diagnostically uncertain alopecia. Reassuringly, telogen effluvium — one of the most common patterns associated with medication or illness — is usually self-limiting and resolves within six to twelve months once the trigger is addressed.

Open communication with your healthcare team remains the most important step in managing any concerns about ezetimibe side effects. All suspected adverse drug reactions can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk — reports from both patients and healthcare professionals contribute to national drug safety monitoring.

Frequently Asked Questions